Replies to post #11635 on Marijuana - Companies & Stocks

[Goodbuddy4863]

GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome:

http://www.marketwatch.com/story/gw-pharmaceuticals-receives-investigational-new-drug-ind-from-fda-for-phase-23-clinical-trial-of-epidiolexr-in-the-treatment-of-dravet-syndrome-2014-05-07

I believe they are in Phase 3 of this Orphaned Status drug [Epidiolex(R]confirmed by the Food and Drug Administration.

http://www.projectcbd.org/news/fda-grants-orphan-drug-status-to-gws-epidiolex-2/